Axsome Therapeutics to Report Fourth Quarter and Full Year 2018 Financial Results on March 14, 2019
March 05 2019 - 7:00AM
Axsome to host conference call and webcast on
Thursday, March 14, 2019 at 8:00 AM Eastern Time
Axsome Therapeutics, Inc. (NASDAQ: AXSM), a clinical-stage
biopharmaceutical company developing novel therapies for the
management of central nervous system (CNS) disorders, today
announced that it will report its financial results for fiscal year
2018 on Thursday, March 14, 2019 before the opening of the U.S.
financial markets. Axsome’s management team will host a conference
call at 8:00 AM Eastern Time on March 14, 2019 to discuss these
results and provide a business update.
To participate in the live conference call,
please dial (844) 698-4029 (toll-free domestic) or (647) 253-8660
(international) and use the conference ID 9087075. A live webcast
of the conference call can be accessed on the “Webcasts &
Presentations” page of the “Investors” section of the Company’s
website at www.axsome.com. A recording of the conference call will
be available on the Company’s website for approximately 30 days
following the live event.
About Axsome Therapeutics,
Inc.
Axsome Therapeutics, Inc. is a clinical-stage
biopharmaceutical company developing novel therapies for the
management of central nervous system (CNS) disorders for which
there are limited treatment options. Axsome’s core CNS product
candidate portfolio includes four clinical-stage candidates,
AXS-05, AXS-07, AXS-09, and AXS-12. AXS-05 is currently in a Phase
3 trial in treatment resistant depression (TRD), a Phase 2/3 trial
in agitation associated with Alzheimer’s disease (AD), and a Phase
2 trial in smoking cessation. AXS-07 is currently in a Phase 3
trial for the acute treatment of migraine. AXS-12 is currently in a
phase 2 trial in narcolepsy. The Axsome Pain and Primary Care
business unit (Axsome PPC) houses Axsome’s pain and primary care
assets, including AXS-02 and AXS-06, and intellectual property
which covers these and related product candidates and molecules
being developed by Axsome and others. AXS-02 is being developed for
osteoporosis, the pain of knee osteoarthritis, and chronic low back
pain. AXS-06 is being developed for osteoarthritis and rheumatoid
arthritis. AXS-02, AXS-05, AXS-06, AXS-07, AXS-09, and AXS-12 are
investigational drug products not approved by the FDA. For more
information, please visit the Company’s website at axsome.com. The
Company may occasionally disseminate material, nonpublic
information on the company website.
Forward Looking Statements
Certain matters discussed in this press release
are “forward-looking statements”. We may, in some cases, use terms
such as “predicts,” “believes,” “potential,” “continue,”
“estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,”
“could,” “might,” “will,” “should” or other words that convey
uncertainty of future events or outcomes to identify these
forward-looking statements. In particular, the Company’s statements
regarding trends and potential future results are examples of such
forward-looking statements. The forward-looking statements include
risks and uncertainties, including, but not limited to, the
success, timing and cost of our ongoing clinical trials and
anticipated clinical trials for our current product candidates,
including statements regarding the timing of initiation and
completion of the trials, futility analyses and receipt of interim
results, which are not necessarily indicative of the final results
of our ongoing clinical trials; our ability to fund additional
clinical trials to continue the advancement of our product
candidates; the timing of and our ability to obtain and maintain
U.S. Food and Drug Administration (“FDA”) or other regulatory
authority approval of, or other action with respect to, our product
candidates (including, but not limited to, FDA’s agreement with the
Company’s plan to discontinue the bupropion treatment arm of the
ADVANCE-1 study in accordance with the independent data monitoring
committee’s recommendations); the potential for the ASCEND clinical
trial to provide a basis for approval of AXS-05 for the treatment
of major depressive disorder and accelerate its development
timeline and commercial path to patients; the Company’s ability to
successfully defend its intellectual property or obtain the
necessary licenses at a cost acceptable to the Company, if at all;
the successful implementation of the Company’s research and
development programs and collaborations; the success of the
Company’s license agreements; the acceptance by the market of the
Company’s product candidates, if approved; and other factors,
including general economic conditions and regulatory developments,
not within the Company’s control. The factors discussed herein
could cause actual results and developments to be materially
different from those expressed in or implied by such statements.
The forward-looking statements are made only as of the date of this
press release and the Company undertakes no obligation to publicly
update such forward-looking statements to reflect subsequent events
or circumstance.
Axsome Contact:Mark Jacobson Senior Vice
President, Operations Axsome Therapeutics, Inc. 25 Broadway, 9th
Floor New York, NY 10004 Tel: 212-332-3243 Email:
mjacobson@axsome.comwww.axsome.com
Axsome Therapeutics (NASDAQ:AXSM)
Historical Stock Chart
From May 2024 to Jun 2024
Axsome Therapeutics (NASDAQ:AXSM)
Historical Stock Chart
From Jun 2023 to Jun 2024